Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.39-1.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CRVS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CRVS — earnings miss
Dated 2026-08-06
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Updates on cash runway will indicate how long Corvus can fund its operations. This affects its ability to continue trials.
Worry ifCash runway extended beyond Q2 2028 in the earnings report.
Less concerning ifCash runway guidance reduced to less than Q2 2028 in the earnings report.
Why it matters: Changes in losses and cash burn will show how well Corvus is managing its finances.
Worry ifOperating losses decrease from -$14.9M in 2026-Q1 to below -$10M.
Less concerning ifOperating losses increase beyond -$14.9M in the next quarter.
Why it matters: Updates on this trial could show if soquelitinib works for more conditions. Good news may attract investors.
Watch forPositive updates or early results from the Phase 2 trial for asthma.
Also watch forNegative updates or delays in the Phase 2 trial for asthma.
Why it matters: Higher operating losses show a worse financial situation. Investors want to know if management can cut costs.
Worry ifOperating losses exceed $14.88M in Q2 2026.
Less concerning ifOperating losses improve or stay below $14.88M in Q2 2026.
Why it matters: Revenue growth is a key driver in the healthcare sector. A drop could signal deeper issues.
Worry ifRevenue growth falls below the sector median.
Less concerning ifRevenue growth remains above the sector median.
Why it matters: If health care growth picks up, it may improve Corvus's market position. This could help its stock.
Supportive ifHealth care revenue growth re-accelerates back toward its highs.
Worry ifHealth care revenue growth continues to decelerate.
Why it matters: Final data will show if the drug is safe and works for atopic dermatitis. Good results could make investors more confident.
Supportive ifFinal data shows at least 75% of patients in cohort 4 achieving EASI 75.
Worry ifFinal data shows less than 50% of patients in cohort 4 achieving EASI 75.
Why it matters: This trial will show if soquelitinib works for patients with atopic dermatitis. Good results could help its market potential.
Supportive ifThe Phase 2 trial showed good results. There was a big improvement in EASI scores.
Worry ifThe trial had bad results. There was no big improvement in EASI scores.
Why it matters: Enrollment progress in this trial is important for soquelitinib's approval. It shows the drug can help treat relapsed/refractory PTCL.
Supportive ifEnrollment reaches or exceeds 150 patients in the Phase 3 trial.
Worry ifEnrollment is stuck or below 150 patients.
Why it matters: This trial could prove soquelitinib works in a new market. Good results may improve its commercial chances.
Supportive ifThe Phase 1b/2 trial in China had good results. There was a big improvement in atopic dermatitis symptoms.
Worry ifThe trial had bad results. There was no big improvement in symptoms.
Why it matters: Watching cash burn is important. It affects the company's ability to fund operations. High cash burn may raise worries about staying in business.
Worry ifCash burn went down a lot compared to previous quarters.
Less concerning ifCash burn goes up or stays high. This shows financial strain.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$205 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $722 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,643 loss on $10,000 · 56.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.